Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

NCT05669430 is registered in ClinicalTrials.gov with GV20 Therapeutics as lead sponsor.

NCT NCT05669430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies
Lead sponsor
GV20 Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 23, 2023
Completion date
September 5, 2027
Enrollment
365 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, endometrial carcinoma (ec), non-small cell lung cancer, pmmr/mss adenocarcinoma of the colon or rectum, refractory cancer, solid tumor, adult, squamous head and neck carcinoma